Page last updated: 2024-12-11
gallium maltolate
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
gallium maltolate: has antineoplastic activity [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
ID Source | ID |
---|---|
PubMed CID | 9846339 |
MeSH ID | M0501003 |
Synonyms (11)
Synonym |
---|
gallium maltolate |
gallium, tris(3-(hydroxy-.kappa.o)-2-methyl-4h-pyran-4-onato-.kappa.o4)-, (oc-6-21)- |
108560-70-9 |
gallium maltolate [inci] |
17LEI49C2G , |
ASYYOZSDALANRF-UHFFFAOYSA-K |
DB05420 |
gallium tris(2-methyl-4-oxo-4h-pyran-3-olate) |
B2699-054157 |
gallium;2-methyl-4-oxopyran-3-olate |
3-bis[(2-methyl-4-oxopyran-3-yl)oxy]gallanyloxy-2-methylpyran-4-one |
Research Excerpts
Actions
Excerpt | Reference | Relevance |
---|---|---|
"Gallium maltolate produced an increase in intracellular reactive oxygen species (ROS) within 2 h of incubation with cells; this effect could be blocked by mitoquinone, a mitochondria-targeted antioxidant." | ( Development of gallium compounds for treatment of lymphoma: gallium maltolate, a novel hydroxypyrone gallium compound, induces apoptosis and circumvents lymphoma cell resistance to gallium nitrate. Chitambar, CR; Purpi, DP; Wereley, JP; Woodliff, J; Yang, M, 2007) | 1.3 |
Pharmacokinetics
Bioavailability
Gallium maltolate (GaM) provides significant gallium bioavailability to people and mice following oral administration and to neonatal foals following intragastric administration. Previous studies indicate that oral Gallium Maltolate would provide a higher bioavailability than oral Ga salts.
Dosage Studied
Excerpt | Relevance | Reference |
---|---|---|
" In conclusion, although infection reduces IT [Ga] and [Fe], a 48 h GaM dosing interval is appropriate for multidose studies in EPE rabbits." | ( Pharmacokinetics of gallium maltolate in Lawsonia intracellularis-infected and uninfected rabbits. Alcorn, J; Allen, AL; Ball, KR; Bernstein, LR; Clark, CR; Dowling, PM; Gebhart, CJ; Hamilton, DL; Mapes, S; Pusterla, N; Sampieri, F; Thompson, J; Vannucci, FA, 2014) | 0.73 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Research
Studies (30)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 3 (10.00) | 29.6817 |
2010's | 22 (73.33) | 24.3611 |
2020's | 5 (16.67) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 38.23
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.
| This Compound (38.23) All Compounds (24.57) |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 2 (6.06%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 2 (6.06%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 29 (87.88%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |